Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409327 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
A Phase 2 study, sponsored by Restorbio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT04409327 is a Phase 2 study that was terminated before completion, run by Restorbio. The registered enrollment target is 36 participants.
The verdict
NCT04409327, a Phase 2 study, was terminated before completion, sponsored by Restorbio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if prophylaxis with RTB101 decreases the severity of laboratory-confirmed COVID-19 among adults ≥ 65 years who reside in a nursing homes in which one or more residents or staff have laboratory-confirmed COVID-19
Interventions
- DRUG Placebo
- DRUG RTB101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-07-11 |
| Est. Completion | 2021-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04409327
The ClinicalTrials.gov registry entry for NCT04409327 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Restorbio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04409327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04409327 about?
NCT04409327 is a clinical study titled "Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes". The purpose of this study is to determine if prophylaxis with RTB101 decreases the severity of laboratory-confirmed COVID-19 among adults ≥ 65 years who reside in a nursing homes in which one or more residents or staff have laboratory-confirmed COVID-19
What is the current status of trial NCT04409327?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2020-07-11. Estimated completion is 2021-01-24.
What interventions are being tested in trial NCT04409327?
The interventions under investigation include: Placebo (DRUG), RTB101 (DRUG).
Who is sponsoring clinical trial NCT04409327?
This trial is sponsored by Restorbio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.